Financial Data and Key Metrics Changes - Total revenue for Q2 2025 decreased by 6% to $11,400,000 compared to $12,100,000 in the same period last year, primarily driven by a decrease in OEM product sales [6][18] - Gross profit for Q2 2025 decreased to $7,100,000 from $7,500,000 in the prior year, while gross profit margin slightly increased to 62.3% from 61.7% [20] - Net loss attributable to stockholders was $3,800,000 or $0.09 per share for Q2 2025, compared to $6,600,000 or $0.19 per share in the prior year [22] Business Line Data and Key Metrics Changes - Revenue for the Advanced Energy segment was relatively flat at $9,700,000 compared to $9,800,000 last year, reflecting a decrease in the volume of single-use handpieces sold domestically [18][19] - OEM segment sales decreased by 29% or approximately $1,700,000 compared to the previous year, with domestic revenue down 11% to $7,800,000 and international revenue down 4% to $3,600,000 [19] Market Data and Key Metrics Changes - The global aesthetic market remains challenging, but the company is identifying key growth opportunities, particularly with the Renuvion product [9][10] - The company has launched Renuvion in China, which is expected to be a significant growth driver due to the emerging middle to upper class and the presence of approximately 5,000 plastic surgeons in the region [12][40] Company Strategy and Development Direction - The company is focused on returning to growth and has appointed two senior sales leaders to enhance its market presence in North America and Europe/Asia [5] - The launch of the Aon system is a key strategic priority, with expectations of significant sales momentum as it addresses current market needs for body contouring [13][16] - The company aims to expand Renuvion's footprint in international markets, with a strong marketing campaign that has exceeded expectations in 2025 [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong early results from Aon presales and a belief that the next decade will be a significant growth period for surgeons [29][30] - The company anticipates a different seasonal revenue pattern due to the timing of Aon product shipments, which could lead to a stronger Q3 and Q4 [20][35] Other Important Information - Cash used in operating activities decreased to $1,200,000 compared to $4,300,000 in the prior year, indicating improved cash and working capital management [22] - The company updated its 2025 revenue guidance to a range of $50,000,000 to $52,000,000, up from previous guidance, reflecting confidence in the Aon launch [23][24] Q&A Session Summary Question: Customer receptivity to Aon and capital purchases in the current market - Management reported that the reaction from doctors to Aon has been overwhelmingly positive, indicating a strong demand for innovation in the market [26][28] Question: Impact of new commercial hires on product launches - The new hires bring extensive experience in the aesthetic space, which is expected to drive the adoption of Aon and Renuvion [31][33] Question: Seasonal revenue patterns and expectations for Q3 and Q4 - Management clarified that while a typical dip from Q2 to Q3 is expected, the launch of Aon could lead to a stronger Q3, with significant shipments anticipated in Q4 [34][35] Question: Market opportunity in China and partnership with GlamMoon - The company sees a substantial opportunity in China, supported by a strong partnership with GlamMoon, which has extensive facilities in the region [40][42]